Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
GERMANTOWN, Md., June 13, 2007 /PRNewswire-FirstCall/ -- Avalon
Pharmaceuticals, Inc. , today announced that it is will provide an
update on the Phase I clinical trial of AVN944
malignancies on Tuesday, June 19, 2007, after the close of the U.S.
financial markets. The Company will a...
Avalon Pharmaceuticals to Present at the American Association for
Cancer Research 2007 Annual Meeting
Pharmaceuticals, Inc. , today announced that avn944
will be the
subject of three poster presentations ...and in vivo experiments that reveal the effects
on blood vessel formation. The presentation will b...acific Time.
Another poster that will discuss avn944
will be presented by the
lab of Dr. Beverly Mitche...
Avalon Pharmaceuticals Announces Positive Interim Results For
AVN944 Phase I Trial
...rly and refractory patients.
Interim data indicate avn944
is well tolerated, has dose-dependent
pharmacokine...ncouraged by the positive interim results
from the avn944
trial," stated Michael Hamilton, M.D., Avalon
Phase II studies."
is an oral small molecule drug that inhibits